Navigation Links
Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
Date:9/3/2008

y oxygen deprivation (hypoxia) at the cellular level. Using a novel mechanism of action, TSC enhances the diffusion of oxygen through blood plasma, increasing the rate of oxygen transport and thus treating the symptoms of hypoxia at their source.

In 2007, the Company successfully completed a Phase I safety study of TSC. This randomized, double-blind, placebo-controlled, dose-escalation study in 40 subjects evaluated the tolerability and pharmacokinetics of an intravenous bolus injection of TSC in healthy human subjects. The study demonstrated that TSC is well tolerated, and raised no significant clinical safety issues in humans at doses higher than the doses being used in ongoing clinical trials.

About Multi-Center Trial in Peripheral Arterial Disease Patients:

This randomized, double-blinded, placebo-controlled trial will consist of four cohorts of 12 patients each, to be enrolled sequentially over an escalating range of TSC dosages. Subjects in the study will receive injections of either TSC or placebo intravenously once daily for five consecutive days. Safety and tolerability will be evaluated in a safety review of each cohort before any patients are enrolled into the next cohort. Patients will be evaluated during the study for safety parameters and for clinical endpoints using a treadmill test at prescribed time points. Follow-up assessments will occur at 5, 14 and 30 days after the last dose. The objectives of the study are to evaluate the safety and pharmacokinetics of multiple doses of TSC; establish a dose-response relationship and effect of TSC on peak walking time and claudication onset time in intermittent claudication patients; determine the effect of TSC on potential hypoxia biomarkers; and evaluate the impact of TSC on quality-of-life parameters using the assessments measured in the Walking Impairment Questionnaire routinely used in PAD research. More information on this trial, designated NCT00725881, can be found on the clinicaltr
'/>"/>

SOURCE Diffusion Pharmaceuticals LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
4. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
5. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
6. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
9. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
10. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
11. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 2015 TWi Pharmaceuticals, Inc. ("TWi", Stock Ticker:4180.TT) ... USA , has obtained state sales licenses ... has been in close contact with the major nationwide ... its own label specialty generic products sold through these ... market. According to IMS Health, the U.S. ...
(Date:4/16/2015)... April 16, 2015  Hologic, Inc. (NASDAQ: ... screening study i published on-line this week ... of the American Cancer Society. The ... of Pittsburgh Medical Center, supports current consensus guidelines ii ... women 30-65 years of age be co-tested with ...
(Date:4/16/2015)... Kenneth C. Frazier , chairman and chief executive officer ... the Board of the Pharmaceutical Research and Manufacturers of America ... John J. Castellani announced that he will be retiring ... to PhRMA Board Frazier formerly held the position ... and CEO of Pfizer, Inc. Also elected were George ...
Breaking Medicine Technology:Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 2Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 3Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5
(Date:4/18/2015)... 2015 More than 2000 styles of ... TheCelebrityDresses.com, the #1 online store carrying celebrity inspired special ... have got their perfect dresses for their prom. For ... prom dresses at TheCelebrityDresses.com would be an ideal choice. ... 2000 prom dresses inspired by the most loved styles ...
(Date:4/18/2015)... 2015 French physician and gastronome Anthelme ... when he uttered, “Tell me what you eat, and ... to cope with stress or sadness has often been ... indicates otherwise. Data collected from their Emotional Eating ... emotional eating, but for different reasons. , Collecting data ...
(Date:4/17/2015)... 2015 Riviera Magazine has ... of the Gallery of Cosmetic Surgery in Newport ... experts. The publication focused on his expertise in ... fat grafting, eyelid surgery, laser resurfacing and rhinoplasty. , ... has resulted in thousands of satisfied patients across ...
(Date:4/17/2015)... April 17, 2015 In Defense of ... following statement: “On Wednesday April 15th, the European Parliament ... a resolution recognizing the Armenian Genocide, “paying tribute, on ... the one-and-a-half million innocent Armenian victims who perished in ... extols the EU for this timely and needed recognition ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 At the ... EcoLuxe Lounge and the “Salute to the Oscars” in ... Beverly Hilton Hotel, overlooking the impressive Los Angeles skyline. ... organized by Debbie Durkin, LA’s leading producer of sustainable ... many of the world’s premier providers of eco-friendly and ...
Breaking Medicine News(10 mins):Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2
... is one of the most common infectious diseases in the ... remains a lack of reliable resources for patients and caregivers ... provides information and tools to guide patients through the stages ... management London, UK, 28 July 2011 - The ...
... interpret mammograms does not improve accuracy, according to a study ... National Cancer Institute. CAD software, used currently ... States, identifies patterns associated with breast cancers and marks potential ... recommendation. To learn whether CAD leads to ...
... News) -- About 10 million injection drug users worldwide have ... study reports. Hepatitis can lead to cirrhosis, liver failure ... that rates of hepatitis C infection among injection drug users ... greater than 80 percent in 12 other countries. ...
... HealthDay Reporter , WEDNESDAY, July 27 (HealthDay News) ... could help hard-to-match patients find a needed kidney faster. ... plasmapheresis -- a machine that filters the blood plasma ... called intravenous immune globulin (IVIG). The combination ...
... Reinberg HealthDay Reporter , WEDNESDAY, July 27 ... that medication can,t control, a new implantable device shows ... below the collarbone, sends a four- to six-volt electrical ... lower blood pressure through a process known as baroreflex ...
... cognitive neuroscience hold great promise for improving current teaching ... scientific discoveries and the application of this knowledge in ... and the Aspen Brain Forum Foundation ... in Aspen, Colorado, "Cognitive Neuroscience of Learning: Implications ...
Cached Medicine News:Health News:PATH B -- a comprehensive support program for patients diagnosed with chronic hepatitis B 2Health News:PATH B -- a comprehensive support program for patients diagnosed with chronic hepatitis B 3Health News:Computer-aided detection does not improve mammogram accuracy 2Health News:Hepatitis Rates Soar Among IV Drug Users, Study Finds 2Health News:Densensitization Procedure Helps Hard-to-Match Kidney Recipients 2Health News:Densensitization Procedure Helps Hard-to-Match Kidney Recipients 3Health News:Implantable Device May Ease Tough-to-Treat Hypertension 2Health News:Implantable Device May Ease Tough-to-Treat Hypertension 3Health News:Conference: Improving K-12 education with cutting-edge cognitive neuroscience research 2
... new software upgrade including fourSight 4D ultrasound ... system offers a wide variety of imaging ... management features that combine to expand the ... ,The Antares system was built on four ...
... evolution in stent technology with no compromises. ... balloon-with great-looking results. With S670's discrete, low-profile ... deliver the excellent clinical results you want. ... with no compromises. It's the stent that ...
Increased stent scaffolding at the proximal end gives optimal lumen support and 6F guide catheter compatibility and improved tracking offer excellent deliverability. Customized balloon lengths for ea...
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
Medicine Products: